Cargando…
TCCR/WSX-1 is a novel angiogenic factor in age-related macular degeneration
PURPOSE: Age-related macular degeneration (AMD) is the major cause of blindness among persons aged 60 years and older. The current approved therapies for AMD are exclusively limited to inhibiting vascular endothelial growth factor. However, substantial improvement in vision occurs in only one-third...
Autores principales: | Sung, Ho Jin, Han, Jung Il, Lee, Ji Won, Uhm, Ki Bang, Heo, Kyun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Molecular Vision
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3272058/ https://www.ncbi.nlm.nih.gov/pubmed/22312192 |
Ejemplares similares
-
Thyroid Cancer and Tumor Collaborative Registry (TCCR)
por: Shats, Oleg, et al.
Publicado: (2016) -
Synthetic anti-angiogenic genomic therapeutics for treatment of neovascular age-related macular degeneration
por: Wang, Jing, et al.
Publicado: (2021) -
WSX1 Expression in Tumors Induces Immune Tolerance via Suppression of Effector Immune Cells
por: Dibra, Denada, et al.
Publicado: (2011) -
Preclinical Efficacy of Pro- and Anti-Angiogenic Peptide Hydrogels to Treat Age-Related Macular Degeneration
por: Acevedo-Jake, Amanda, et al.
Publicado: (2021) -
Red Light‐Triggered Anti‐Angiogenic and Photodynamic Combination Therapy of Age‐Related Macular Degeneration
por: Xu, Shuting, et al.
Publicado: (2023)